Second generation, orally active, antimalarial, artemisinin-derived trioxane dimers with high stability, efficacy, and anticancer activity.
about
Artemisinin triggers a G1 cell cycle arrest of human Ishikawa endometrial cancer cells and inhibits cyclin-dependent kinase-4 promoter activity and expression by disrupting nuclear factor-κB transcriptional signaling.Development of artemisinin compounds for cancer treatment.Drug discovery for malaria: a very challenging and timely endeavorArtemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs.Artemisinin-derived dimer phosphate esters as potent anti-cytomegalovirus (anti-CMV) and anti-cancer agents: a structure-activity study.Evaluation of artemisinins for the treatment of acute myeloid leukemia.Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression.Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells.Dimeric approaches to anti-cancer chemotherapeutics.Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction.Anticancer activities of artemisinin and its bioactive derivatives.Artemisinin and its derivatives: a novel class of anti-malarial and anti-cancer agents.Antimalarial Preclinical Drug Development: A Single Oral Dose of A 5-Carbon-linked Trioxane Dimer Plus Mefloquine Cures Malaria-Infected Mice.The medicinal and pharmaceutical importance of Dendrobium species.Malaria-infected mice are cured by a single oral dose of new dimeric trioxane sulfones which are also selectively and powerfully cytotoxic to cancer cells.Synthesis and antimalarial efficacy of two-carbon-linked, artemisinin-derived trioxane dimers in combination with known antimalarial drugs.Chemopreventive effect of artesunate in 1,2-dimethylhydrazine-induced rat colon carcinogenesis.Biological mechanisms of action of novel C-10 non-acetal trioxane dimers in prostate cancer cell lines.Antimalarial chemotherapy: artemisinin-derived dimer carbonates and thiocarbonates.4-N-, 4-S-, and 4-O-chloroquine analogues: influence of side chain length and quinolyl nitrogen pKa on activity vs chloroquine resistant malaria.Towards multivalent CD1d ligands: synthesis and biological activity of homodimeric α-galactosyl ceramide analogues.4-aminoquinoline-triazine-based hybrids with improved in vitro antimalarial activity against CQ-sensitive and CQ-resistant strains of Plasmodium falciparum.Synthesis and antimalarial activity of new 4-amino-7-chloroquinolyl amides, sulfonamides, ureas and thioureas.Overcoming drug resistance to heme-targeted antimalarials by systematic side chain variation of 7-chloro-4-aminoquinolines.The survival times of malaria-infected mice are prolonged more by several new two-carbon-linked artemisinin-derived dimer carbamates than by the trioxane antimalarial drug artemether.1,2-Bis[(3,6,9-trimethyl-3,12-ep-oxy-3,4,5,5a,6,7,8,8a,9,10,12,12a-dodeca-hydro-pyrano[4,3-j][1,2]benzodioxepin-4-yl)-oxy]ethanePotential sonodynamic anticancer activities of artemether and liposome-encapsulated artemether.Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1alpha activation in C6 glioma cells.
P2860
Q34231069-D80A7B73-76C7-4579-8CEF-4E48D01B4165Q34296810-1976D06F-2E46-4B57-A577-65D61BE17C57Q36012422-8C4ADBDD-7E1A-4E1F-B2C2-27F5C40D3E20Q36916456-74B28B71-5D2A-4149-BE0C-C1DC222CF7BEQ36938452-91F23917-07E5-4FEA-B66D-637B4743DD1CQ37033027-64A1B157-B143-4CF7-A038-99BC85C2C7AEQ37068031-D797EF4C-AF30-4288-9457-A94F264DB58FQ37090690-FF0BCEED-EDD4-4A00-ABF4-4641B8D9DC50Q37294055-BEC328A5-7DDC-4C66-8798-40E98C21E61CQ37365121-80D1E0FB-E273-4606-B337-428B03BD8D26Q37626137-48717301-B0CC-41D3-BF65-70878C8D46F9Q37683458-7E2EC5EB-038B-425F-AE75-305FCD619333Q38497186-950241DC-104E-4DDC-B7A1-568641CBADCBQ39135853-D2700260-FA46-408F-8888-DDC606BAC182Q39888577-17C3E8CA-2EDC-441A-8C55-71B9805CD524Q39961767-F875CB90-5BBB-431D-881A-0B6D22F95AB2Q41129171-B78AF2FE-0EEE-4545-B632-561C6F45A16BQ41273184-376CA5D8-2FA3-456F-9C9B-69B8995FF998Q41462510-BBB872EA-081F-41F7-8181-24EB7A5CD317Q41772843-12C82050-2E63-4C60-8F95-91CCE9584A21Q41841063-49E27BE5-F024-485D-B2BF-45DF89AFD550Q41927067-FA78129F-986B-4539-ABFF-5779D49CD6FDQ41939714-88050BE1-84AE-48ED-8A10-B7AE323F4A1BQ41941261-75B82086-3761-43C4-90CD-4FA72F063C70Q42000397-CCF91E87-D8C0-4D14-A1AC-731DAF3FC3C0Q42032786-C38D5C05-516D-46C6-B1DF-27B55D1CA1DEQ46771212-63E66A94-121A-46B0-8175-A983794A55A4Q55467925-9EC10523-C2A5-4063-BDC1-A64BF814EA41
P2860
Second generation, orally active, antimalarial, artemisinin-derived trioxane dimers with high stability, efficacy, and anticancer activity.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Second generation, orally acti ...... cacy, and anticancer activity.
@en
type
label
Second generation, orally acti ...... cacy, and anticancer activity.
@en
prefLabel
Second generation, orally acti ...... cacy, and anticancer activity.
@en
P2093
P356
P1476
Second generation, orally acti ...... cacy, and anticancer activity.
@en
P2093
Amy A Narducci Sarjeant
Astrid C Baege
Gary H Posner
Ik-Hyeon Paik
Tanzina Labonte
Theresa A Shapiro
P304
P356
10.1021/JM058288W
P407
P577
2006-05-01T00:00:00Z